Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review

Research output: Contribution to journalReviewResearchpeer-review

  1. Emotional cognition subgroups in mood disorders: Associations with familial risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Apps for mental health care: The raise of digital psychiatry

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Autism comorbidities show elevated female-to-male odds ratios and are associated with the age of first autism diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Emotional cognition subgroups in mood disorders: Associations with familial risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Cognitive impairments are a core feature of several neuropsychiatric disorders. A common biomarker for pro-cognitive effects may provide a much-needed tool to select amongst candidate treatments targeting cognition. The hippocampus is a promising biomarker for target-engagement due to the illness-associated morphological hippocampal changes across unipolar disorder (UD), bipolar disorder (BD) and schizophrenia (SCZ). Following the PRISMA guidelines, we searched PubMed and Embase, for clinical trials targeting cognition across neuropsychiatric disorders, with longitudinal structural magnetic resonance imaging (MRI) measures of the hippocampus. Five randomized and three open-label trials were included. Hippocampal volume increases were associated with treatment-related cognitive improvement following treatment with erythropoietin across UD, BD and SCZ, lithium treatment in BD and aerobic exercise in SCZ. Conversely, an exercise intervention in UD showed no effect on hippocampal volume or cognition. Together, these observations point to hippocampal volume change as a putative biomarker-model for cognitive improvement. Future cognition trials are encouraged to include MRI assessments pre- and post-treatment to assess the validity of hippocampal changes as a biomarker for pro-cognitive effects.

Original languageEnglish
JournalEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Volume29
Issue number3
Pages (from-to)319-329
Number of pages11
ISSN0924-977X
DOIs
Publication statusPublished - 1 Mar 2019

    Research areas

  • Cognition Disorders/etiology, Hippocampus/diagnostic imaging, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging/methods, Mental Disorders/complications, Treatment Outcome, Biomarker, Schizophrenia, Bipolar disorder, Unipolar disorder, Neuropsychiatric disorders, Hippocampus

ID: 58079738